Novo Nordisk's Pre-Market Slide Sets Up a High-Stakes Reckoning

Novo Nordisk faces a pivotal H1 report amid a 25% stock drop, Wegovy price cuts, and fierce competition from Eli Lilly.

The Danish drugmaker enters Wednesday's interim report carrying the heaviest baggage of its recent history. Novo Nordisk shares tumbled 8.48 percent on Friday to close at EUR 40.90, leaving the stock 25.45 percent below its 52-week high of EUR 54.86 reached in January. The sell-off lands just days before the company publishes its first-half results on August 5, 2026, ahead of the market open, with a management call scheduled for 1:00 PM CET.

A Forecast Already Tempered

The numbers themselves arrive against a backdrop of lowered expectations. After the first quarter, management nudged its full-year guidance upward, now projecting adjusted sales and operating profit to decline between 4 and 12 percent at constant exchange rates — a modest improvement over the prior range. Yet that revision owed more to accounting mechanics than commercial momentum. First-quarter revenue climbed to DKK 96.8 billion, a 32 percent increase at constant currencies, but the bulk of that growth came from the non-cash release of a DKK 26.8 billion provision.

The company has already flagged 2026 as a potential "valley" year, with operating profit expected to shrink on a currency-adjusted basis. Any deviation from that trajectory could move the needle on Wednesday.

The Price-Cut Conundrum

Beyond the immediate earnings readout, a structural challenge looms. Novo Nordisk has committed to slashing Wegovy prices by 50 percent and Ozempic by 35 percent starting January 2027 — a move designed to defend market share but one that inevitably caps future cash flows. The market's reaction has been unforgiving: the stock now trades at a price-to-earnings ratio of roughly 12, historically cheap for the sector, with a dividend yield near 3 percent.

The contrast with rival Eli Lilly could hardly be starker. Lilly, which also reports on August 5, raised its 2026 revenue guidance to between $82 billion and $85 billion, powered by Mounjaro and Zepbound. First-quarter growth came in at 55.55 percent for the Indianapolis-based company. Novo Nordisk, meanwhile, is cutting 9,000 jobs and bracing for declining adjusted sales. The gap between the two GLP-1 heavyweights widens with each passing quarter.

What Analysts Will Scrutinize

Attention will center on the oral formulation of Wegovy, which saw strong demand after its launch earlier this year. The critical question: how many patients persist with the tablet through the dose-escalation phase. That metric determines whether prescription headlines translate into durable per-patient revenue.

A positive read-through would see weekly US prescription numbers hold steady, with international launches — including the UK — adding incremental sales. A negative outcome would emerge if US pricing erodes faster than volume can compensate, suggesting the recent recovery was merely a flash in the pan.

The international rollout also takes center stage. Novo Nordisk begins introducing oral Wegovy outside the US in the second half of the year, alongside the Medicare Part D obesity pilot program that commenced on July 1, 2026. Investors will also seek updates on manufacturing capacity, as the company continues grappling with supply constraints and integrating additional production sites to meet global demand.

Technicals and Timing

Friday's decline pushed the stock into precarious chart territory. At EUR 40.90, the share price hovers just above its 200-day moving average of EUR 40.35 — a level technicians view as critical to avoid a further downward spiral. The 14-day relative strength index sits at 41.8, approaching oversold conditions without yet crossing the threshold.

The timing of the report adds another layer of intrigue. Both Novo Nordisk and Eli Lilly publish on the same day, sharpening the competitive narrative in the obesity drug market. Lilly's oral candidate Foundayo (orforglipron) has gained meaningful traction since its April 2026 launch, intensifying pressure on the Danish group's franchise.

A Turnaround Thesis — or the Beginning of the End?

Some market observers see opportunity in the depressed valuation. With a P/E of around 12 and a dividend yield of roughly 3 percent, a turnaround case can be made — provided investors are willing to endure the 2027 pricing transition. New late-stage pipeline data, particularly on the combination therapy CagriSema, could also shift sentiment.

Wednesday will determine which narrative prevails. If weekly US oral Wegovy prescriptions hold firm, the turnaround thesis gains credibility. If pricing dynamics deteriorate further, Friday's sell-off may prove to be merely the opening act. The ZEUS study setback in late July already dealt a heavy blow to investor confidence; the midyear report now offers management a chance to rebuild it — or deepen the damage.